Endologix Company Profile (NASDAQ:ELGX)

About Endologix (NASDAQ:ELGX)

Endologix logoEndologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ELGX
  • CUSIP: 29266S10
  • Web: www.endologix.com
  • Market Cap: $409.9 million
  • Outstanding Shares: 82,975,000
Average Prices:
  • 50 Day Moving Avg: $6.62
  • 200 Day Moving Avg: $6.86
  • 52 Week Range: $4.20 - $14.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.51
  • P/E Growth: -0.18
Sales & Book Value:
  • Annual Revenue: $193.17 million
  • Price / Sales: 2.12
  • Book Value: $1.14 per share
  • Price / Book: 4.33
  • EBIDTA: ($61,290,000.00)
  • Net Margins: -78.53%
  • Return on Equity: -39.12%
  • Return on Assets: -13.36%
  • Debt-to-Equity Ratio: 1.31%
  • Current Ratio: 2.47%
  • Quick Ratio: 1.75%
  • Average Volume: 1.54 million shs.
  • Beta: 0.87
  • Short Ratio: 12.53

Frequently Asked Questions for Endologix (NASDAQ:ELGX)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. The company earned $42.60 million during the quarter, compared to analysts' expectations of $41.15 million. Endologix had a negative return on equity of 39.12% and a negative net margin of 78.53%. Endologix's revenue was up .5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.25) EPS. View Endologix's Earnings History.

Where is Endologix's stock going? Where will Endologix's stock price be in 2017?

11 equities research analysts have issued 12 month price objectives for Endologix's stock. Their forecasts range from $5.00 to $16.00. On average, they expect Endologix's stock price to reach $8.32 in the next year. View Analyst Ratings for Endologix.

What are analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:

  • 1. Canaccord Genuity analysts commented, "Date and time of first dissemination: May 18, 2017, 12:09 ET Date and time of production: May 18, 2017, 12:09 ET Target Price / Valuation Methodology: CRH Medical Corporation – CRHM Price target of $8 is based on 15x 2018E adj-EBITDA to common, a premium to its peer group of outsourced health care services providers. We believe that is justified given the faster growth and higher margin profile of CRHM relative to peers. Risks to achieving Target Price / Valuation: CRH Medical Corporation – CRHM Negative reimbursement rate cuts or other regulatory changes could adversely impact market for anesthesia services. Should the level of acquisitions not meet our expectations, or should acquisitions not integrate and contribute to profitability as expected, CRH financial results could be below our expectations. Margin compression is possible as M&A activity ramps up." (5/18/2017)
  • 2. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (5/5/2017)

Are investors shorting Endologix?

Endologix saw a decline in short interest during the month of April. As of April 13th, there was short interest totalling 19,411,895 shares, a decline of 6.4% from the March 31st total of 20,740,080 shares. Based on an average daily volume of 1,117,969 shares, the short-interest ratio is currently 17.4 days. Approximately 25.8% of the shares of the stock are sold short.

Who are some of Endologix's key competitors?

Who owns Endologix stock?

Endologix's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Brown Capital Management LLC (10.59%), BROWN CAPITAL MANAGEMENT LLC (10.58%), Vanguard Group Inc. (7.58%), Columbia Wanger Asset Management LLC (7.27%), Camber Capital Management LLC (7.23%) and TimesSquare Capital Management LLC (4.60%). Company insiders that own Endologix stock include Amanda L Depalma, Charles Steele Love, Dan Lemaitre, Gregory D Waller, Guido J Neels, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III, Thomas Wilder, Todd Abraham and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Who sold Endologix stock? Who is selling Endologix stock?

Endologix's stock was sold by a variety of institutional investors in the last quarter, including Pioneer Investment Management Inc., Ameriprise Financial Inc., Bank of America Corp DE, FMR LLC, Elk Creek Partners LLC, Columbia Wanger Asset Management LLC, Paradigm Capital Management Inc. NY and Alambic Investment Management L.P.. Company insiders that have sold Endologix stock in the last year include Amanda L Depalma, Gregory D Waller, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov and Robert D Mitchell. View Insider Buying and Selling for Endologix.

Who bought Endologix stock? Who is buying Endologix stock?

Endologix's stock was purchased by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Camber Capital Management LLC, Redmile Group LLC, Point72 Asset Management L.P., Great West Life Assurance Co. Can, TimesSquare Capital Management LLC, Endurant Capital Management LP and Mackenzie Financial Corp. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III, Todd Abraham and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy Endologix stock?

Shares of Endologix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Endologix stock cost?

One share of Endologix stock can currently be purchased for approximately $4.94.

Analyst Ratings

Consensus Ratings for Endologix (NASDAQ:ELGX) (?)
Ratings Breakdown: 10 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.09)
Consensus Price Target: $8.32 (68.38% upside)

Analysts' Ratings History for Endologix (NASDAQ:ELGX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Oppenheimer Holdings Inc.DowngradeOutperform -> Market Perform$6.00MediumView Rating Details
5/18/2017Royal Bank of CanadaReiterated RatingHoldMediumView Rating Details
5/18/2017BMO Capital MarketsReiterated RatingHold$5.00HighView Rating Details
5/18/2017Canaccord GenuityReiterated RatingHold$5.00HighView Rating Details
5/18/2017StephensDowngradeOverweight -> Equal Weight$6.00HighView Rating Details
5/18/2017BTIG ResearchDowngradeBuy -> Neutral$7.00HighView Rating Details
5/18/2017Stifel NicolausDowngradeBuy -> Hold$10.00 -> $5.50HighView Rating Details
12/7/2016Leerink SwannReiterated RatingMarket Perform$11.00 -> $8.00N/AView Rating Details
12/4/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$14.00 -> $10.00N/AView Rating Details
11/16/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
8/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/AView Rating Details
2/22/2016Credit Suisse Group AGLower Price TargetOutperform$16.00 -> $10.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Endologix (NASDAQ:ELGX)
Earnings by Quarter for Endologix (NASDAQ:ELGX)
Earnings History by Quarter for Endologix (NASDAQ:ELGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.24)($0.18)$41.15 million$42.60 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.19)($0.22)$48.69 million$47.46 millionViewListenView Earnings Details
11/1/2016Q316($0.15)($0.11)$51.83 million$52.12 millionViewN/AView Earnings Details
8/2/2016Q2($0.20)($0.20)$46.30 million$51.00 millionViewListenView Earnings Details
5/9/2016Q1($0.24)($0.25)$38.78 million$42.40 millionViewN/AView Earnings Details
2/22/2016Q4($0.16)($0.08)$39.97 million$39.20 millionViewListenView Earnings Details
10/26/2015Q315($0.14)($0.13)$38.12 million$38.20 millionViewListenView Earnings Details
8/3/2015Q215($0.13)($0.18)$39.47 million$39.50 millionViewN/AView Earnings Details
4/29/2015Q115($0.13)($0.14)$37.94 million$36.70 millionViewN/AView Earnings Details
2/25/2015Q414($0.10)($0.11)$38.10 million$38.80 millionViewN/AView Earnings Details
10/30/2014Q314($0.13)($0.13)$37.00 million$37.20 millionViewListenView Earnings Details
7/30/2014Q214($0.08)($0.06)$36.50 million$38.30 millionViewListenView Earnings Details
4/30/2014Q114($0.08)($0.08)$32.24 million$33.30 millionViewListenView Earnings Details
2/27/2014Q413($0.05)($0.05)$35.80 million$35.25 millionViewListenView Earnings Details
10/30/2013Q313($0.05)$0.01$32.47 million$33.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.06)($0.03)$33.94 million$34.00 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)($0.15)$29.26 million$29.80 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.03)($0.09)$29.03 million$29.22 millionViewN/AView Earnings Details
10/25/2012($0.04)($0.03)ViewN/AView Earnings Details
7/26/2012($0.04)($0.09)ViewN/AView Earnings Details
4/26/2012($0.06)($0.07)ViewN/AView Earnings Details
2/22/2012($0.05)($0.06)ViewN/AView Earnings Details
10/27/2011($0.05)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Endologix (NASDAQ:ELGX)
2017 EPS Consensus Estimate: ($0.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.22)($0.22)
Q2 20172($0.18)($0.16)($0.17)
Q3 20172($0.16)($0.11)($0.14)
Q4 20172($0.13)($0.12)($0.13)
(Data provided by Zacks Investment Research)


Dividend History for Endologix (NASDAQ:ELGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endologix (NASDAQ:ELGX)
Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Dan LemaitreDirectorBuy22,522$4.43$99,772.46View SEC Filing  
5/19/2017Guido J NeelsDirectorBuy20,000$4.32$86,400.00View SEC Filing  
5/19/2017Robert D MitchellPresidentBuy2,200$4.32$9,504.00View SEC Filing  
12/14/2016John D McdermottCEOBuy10,000$6.67$66,700.00View SEC Filing  
12/14/2016Thomas F Zenty IIIDirectorBuy3,000$6.51$19,530.00View SEC Filing  
12/13/2016Vaseem MahboobCFOBuy20,000$6.25$125,000.00View SEC Filing  
11/18/2016Guido J NeelsDirectorBuy13,000$7.69$99,970.00View SEC Filing  
8/19/2016Jose A LimaVPSell4,710$11.68$55,012.80View SEC Filing  
8/5/2016Michael V ChobotovInsiderSell14,000$12.40$173,600.00View SEC Filing  
6/3/2016Gregory D WallerDirectorSell7,800$12.86$100,308.00View SEC Filing  
6/1/2016Amanda L DepalmaVPSell689$12.55$8,646.95View SEC Filing  
6/1/2016John D McdermottCEOSell6,116$12.55$76,755.80View SEC Filing  
6/1/2016Joseph A DejohnInsiderSell957$12.55$12,010.35View SEC Filing  
6/1/2016Robert D MitchellPresidentSell2,294$12.55$28,789.70View SEC Filing  
5/26/2016James Edward MachekVPSell6,500$12.76$82,940.00View SEC Filing  
1/26/2016Charles Steele LoveVPSell4,280$7.72$33,041.60View SEC Filing  
11/3/2015Guido J NeelsDirectorBuy11,000$9.32$102,520.00View SEC Filing  
11/3/2015Todd AbrahamVPBuy2,500$8.85$22,125.00View SEC Filing  
11/2/2015John D McdermottCEOBuy20,000$8.90$178,000.00View SEC Filing  
9/3/2015Jose A LimaVPSell1,923$12.60$24,229.80View SEC Filing  
5/26/2015Thomas WilderDirectorSell3,790$16.08$60,943.20View SEC Filing  
5/20/2015Jose A LimaVPSell1,872$16.75$31,356.00View SEC Filing  
4/6/2015Robert D MitchellPresidentSell45,000$17.33$779,850.00View SEC Filing  
12/12/2014Charles Steele LoveVPSell10,000$13.95$139,500.00View SEC Filing  
11/18/2014Charles Steele LoveVPBuy2,000$11.70$23,400.00View SEC Filing  
11/4/2014Guido J NeelsDirectorBuy10,000$11.21$112,100.00View SEC Filing  
11/4/2014John D McdermottCEOBuy25,000$11.25$281,250.00View SEC Filing  
8/4/2014Thomas WilderDirectorSell3,500$13.68$47,880.00View SEC Filing  
6/12/2014Robert D MitchellPresidentSell18,271$14.23$259,996.33View SEC Filing  
6/10/2014Robert D MitchellPresidentSell8,516$14.20$120,927.20View SEC Filing  
8/14/2013Stefan SchreckVPSell25,000$16.18$404,500.00View SEC Filing  
8/13/2013Stefan SchreckVPSell29,000$15.88$460,520.00View SEC Filing  
8/5/2013Gary SorsherVPSell12,483$15.98$199,478.34View SEC Filing  
8/5/2013John McdermottCEOSell165,000$16.00$2,640,000.00View SEC Filing  
8/2/2013Todd AbrahamVPSell9,994$15.90$158,904.60View SEC Filing  
8/1/2013John D McdermottCEOSell15,000$15.83$237,450.00View SEC Filing  
6/3/2013Thomas WilderDirectorSell22,500$13.25$298,125.00View SEC Filing  
5/28/2013Leonard M GreensteinVPSell1,253$14.01$17,554.53View SEC Filing  
12/28/2012Robert John KristCFOSell37,530$14.06$527,671.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Endologix (NASDAQ:ELGX)
Latest Headlines for Endologix (NASDAQ:ELGX)
americanbankingnews.com logoFY2018 EPS Estimates for Endologix, Inc. Decreased by Leerink Swann (ELGX)
www.americanbankingnews.com - May 24 at 1:08 PM
americanbankingnews.com logoInsider Buying: Endologix, Inc. (ELGX) Director Acquires 22,522 Shares of Stock
www.americanbankingnews.com - May 23 at 4:32 PM
americanbankingnews.com logoInsider Buying: Endologix, Inc. (ELGX) Director Purchases 20,000 Shares of Stock
www.americanbankingnews.com - May 23 at 1:27 PM
americanbankingnews.com logoEndologix, Inc. to Post FY2018 Earnings of ($0.59) Per Share, Oppenheimer Holdings Forecasts (ELGX)
www.americanbankingnews.com - May 22 at 8:50 AM
seekingalpha.com logoEndologix Needs Confirmatory Study For Nellix EVAS System - Seeking Alpha
seekingalpha.com - May 20 at 9:53 PM
rttnews.com logoEndologix Inc. (ELGX) Plunged To A New Low After FDA Meeting
www.rttnews.com - May 19 at 8:05 AM
finance.yahoo.com logoWhy Endologix, Inc. Is Getting Crushed Today
finance.yahoo.com - May 19 at 8:05 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Lowered to "Market Perform" at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 18 at 10:56 PM
americanbankingnews.com logoRoyal Bank of Canada Reaffirms Hold Rating for Endologix, Inc. (ELGX)
www.americanbankingnews.com - May 18 at 9:40 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Earns Hold Rating from BMO Capital Markets
www.americanbankingnews.com - May 18 at 5:20 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Walmart, L Brands, Endologix, Cisco, Stein Mart - Nasdaq
www.nasdaq.com - May 18 at 5:14 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - May 18 at 1:32 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Stock Rating Lowered by Stifel Nicolaus
www.americanbankingnews.com - May 18 at 1:00 PM
feeds.benzinga.com logoAnalyst On Endologix: No Sense In Downgrading Now
feeds.benzinga.com - May 18 at 11:43 AM
rttnews.com logoEndologix Inc. (ELGX) Has Dropped To A New Low For The Year
www.rttnews.com - May 18 at 10:28 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Stock Rating Lowered by BTIG Research
www.americanbankingnews.com - May 18 at 9:54 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Rating Lowered to Equal Weight at Stephens
www.americanbankingnews.com - May 18 at 9:14 AM
seekingalpha.com logoEndologix to run new confirmatory study to support U.S. marketing application for Nellix EVAS; FDA OK expected in 2020; shares down 3% after hours
seekingalpha.com - May 17 at 5:14 PM
streetinsider.com logoEndologix (ELGX) Offers Regulatory Status Update for Nellix Endovascular Aneurysm Sealing System - StreetInsider.com
www.streetinsider.com - May 17 at 4:58 PM
finance.yahoo.com logoEndologix Provides an Update on the Nellix® Endovascular Aneurysm Sealing System U.S. Regulatory Status
finance.yahoo.com - May 17 at 4:58 PM
americanbankingnews.com logo$47.64 Million in Sales Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - May 17 at 10:54 AM
finance.yahoo.com logoEndologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : May 16, 2017
finance.yahoo.com - May 16 at 11:56 AM
americanbankingnews.com logo-$0.19 Earnings Per Share Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - May 15 at 2:24 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 12 at 11:20 AM
finance.yahoo.com logoETFs with exposure to Endologix, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:35 PM
finance.yahoo.com logoEndologix, Inc. :ELGX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 4:54 PM
seekingalpha.com logoEndologix's (ELGX) CEO John McDermott on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 7 at 10:31 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 5 at 10:10 PM
finance.yahoo.com logoEdited Transcript of ELGX earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 5 at 5:07 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 5 at 12:38 AM
marketbeat.com logoEndologix reports 1Q loss
marketbeat.com - May 4 at 5:30 PM
finance.yahoo.com logoEndologix Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 5:05 PM
seekingalpha.com logoEndologix misses by $0.05, beats on revenue
seekingalpha.com - May 4 at 4:50 PM
nasdaq.com logoImplied Volatility Surging for Endologix (ELGX) Stock Options - Nasdaq
www.nasdaq.com - May 3 at 8:48 AM
prnewswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an ... - PR Newswire (press release)
www.prnewswire.com - May 3 at 8:48 AM
finance.yahoo.com logoImplied Volatility Surging for Endologix (ELGX) Stock Options
finance.yahoo.com - May 2 at 7:31 PM
americanbankingnews.com logoEndologix (ELGX) Receives Daily News Impact Rating of 0.13
www.americanbankingnews.com - May 2 at 5:12 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Endologix, Inc. - ELGX
finance.yahoo.com - May 1 at 4:47 PM
americanbankingnews.com logoEndologix (ELGX) Receives Media Impact Score of 0.04
www.americanbankingnews.com - April 29 at 12:53 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Sees Large Decrease in Short Interest
www.americanbankingnews.com - April 28 at 7:14 AM
americanbankingnews.com logoEndologix (ELGX) Earns News Sentiment Rating of -0.03
www.americanbankingnews.com - April 26 at 3:00 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Expected to Announce Quarterly Sales of $41.08 Million
www.americanbankingnews.com - April 26 at 10:26 AM
americanbankingnews.com logoZacks Investment Research Downgrades Endologix, Inc. (ELGX) to Sell
www.americanbankingnews.com - April 25 at 11:34 PM
businesswire.com logoEndologix, Inc. to Host an Investor Conference Call to Discuss its Nellix® Endovascular Aneurysm Sealing System Presentation at the Society of Vascular Surgery Annual Meeting ...
www.businesswire.com - April 25 at 11:37 AM
americanbankingnews.com logo Analysts Anticipate Endologix, Inc. (ELGX) to Post -$0.23 Earnings Per Share
www.americanbankingnews.com - April 24 at 10:26 PM
finance.yahoo.com logoEndologix, Inc. to Host an Investor Conference Call to Discuss its Nellix® Endovascular Aneurysm Sealing System ... - Yahoo Finance
finance.yahoo.com - April 24 at 4:48 PM
finance.yahoo.com logoEndologix, Inc. – Value Analysis (NASDAQ:ELGX) : April 24, 2017
finance.yahoo.com - April 24 at 4:48 PM
finance.yahoo.com logoEndologix, Inc. to Host an Investor Conference Call to Discuss its Nellix® Endovascular Aneurysm Sealing System Presentation at the Society of Vascular Surgery Annual Meeting on June 3, 2017
finance.yahoo.com - April 24 at 4:48 PM
americanbankingnews.com logoEndologix (ELGX) Earns Media Impact Score of 0.15
www.americanbankingnews.com - April 23 at 10:02 PM
finance.yahoo.com logoEndologix, Inc. breached its 50 day moving average in a Bullish Manner : ELGX-US : April 21, 2017
finance.yahoo.com - April 21 at 12:03 PM



Endologix (ELGX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff